Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System
- Inspira Technologies receives U.S. Patent approval for orbiting blood oxygenation delivery system.
- 16 claims of the innovation are found to be novel.
- The VORTX™ system aims to revolutionize medical oxygenation by eliminating damage caused by fiber membranes.
- The INSPIRA ART500 device is designed to empower breathing in awake patients by delivering oxygen volume directly into the blood.
- The device continuously measures blood parameters in real-time and is equipped with the HYLA blood sensor for detecting changes in patient condition.
- CEO Dagi Ben-Noon views the innovation as a monumental advancement in blood oxygenation technologies.
- None.
Insights
The U.S. Patent approval for Inspira Technologies' orbiting blood oxygenation delivery system signifies a potential shift in the medical technology landscape, particularly within respiratory treatments. The patented technology's ability to oxygenate blood without fiber membranes addresses a critical pain point in current mechanical ventilation—a process known for causing damage to blood cells due to friction and shear forces. By potentially reducing hemolysis and other blood-related complications, this system could improve patient outcomes significantly.
From a research perspective, the innovation could lead to a reduction in the risks associated with traditional mechanical ventilation, such as blood clotting and immune system activation. The continuous real-time blood monitoring feature of the INSPIRA ART500 device, coupled with the HYLA blood sensor, presents a significant advancement in patient care, offering the possibility of immediate response to changes in patient condition.
In financial terms, Inspira Technologies' patent approval positions the company favorably within the $19 billion mechanical ventilation market. The market's size indicates a substantial opportunity for growth and revenue, particularly if the INSPIRA ART500 device delivers on its promise to provide a less invasive and more effective alternative to current mechanical ventilators. It is crucial to monitor the company's progress through clinical trials and regulatory approvals to better assess the potential impact on its financial performance.
Investors may view this news as a positive development, but they should also consider the risks associated with medical technology companies, such as the lengthy and uncertain FDA approval process and the challenges of commercialization. The company's statement that its products have not yet been tested or used in humans suggests that there is still a considerable journey ahead before the technology can generate revenue.
The relevance of Inspira Technologies' patent in the healthcare industry cannot be overstated. Mechanical ventilation is a critical component in intensive care units worldwide and any technology that can reduce its invasiveness and associated risks represents a significant advancement. The INSPIRA ART500 device's potential to allow patients to remain awake during treatment could lead to shorter hospital stays and reduced healthcare costs, which are critical considerations as healthcare systems globally aim to improve efficiency and patient care.
Additionally, the device's real-time monitoring capabilities align with the industry's shift towards personalized medicine and data-driven care. This trend is increasingly becoming a standard expectation in medical technology development. The ability to provide decision-supportive data to physicians may enhance the quality of care and align with the broader trend of integrating technology into patient management.
RA'ANANA,
The orbiting blood oxygenation delivery system (VORTX™) is designed to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical landscape. The current fiber technologies used for blood oxygenation cause substantial damage to the patient's blood cells. Unlike the natural laminar blood flow in blood vessels inside the body, in existing fiber oxygenators, the blood is "forced" to flow in a harmful turbulent flow through many layers of fibers while experiencing friction and shear forces within the fiber walls. Since the fiber fabric is a significant resistor to blood flow, high-pressure differences are formed and cause significant damage to the various blood components, including, high hemolysis (breakdown of red cells), damage to white blood cells, activation of the inflammatory system in the body, activation of the immune system, and blood clotting.
We believe that the orbiting blood oxygenation delivery system is another potentially game-changing core technology of the INSPIRA ART500 device, in targeting the
The INSPIRA ART500 is a breakthrough device, designed to empower breathing in patients that are awake, by continuously measuring the patient's blood parameters in real-time, and delivering needed oxygen volume straight into the blood. As the INSPIRA ART500 is to be equipped with the HYLA blood sensor, it is being designed to continuously scan the patient's blood, potentially allowing for real-time detection of changes in patient condition and providing physicians with decision-supportive data.
CEO of Inspira Technologies Dagi Ben-Noon: "We believe that this is a monumental advancement in the landscape of blood oxygenation technologies and a pivotal milestone and another key indicator of the INSPIRA ART500's core technological portfolio."
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity. For more information, please visit our corporate website: https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD. All rights reserved.
Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
For more details:
Adi Shmueli
Public Relations Manager
Inspira Technologies
info@inspirao2.com
+972-9-9664485
View original content:https://www.prnewswire.com/news-releases/inspira-receives-first-ever-us-patent-approval-for-an-orbiting-blood-oxygenation-delivery-system-302061765.html
SOURCE Inspira Technologies
FAQ
What is the core technology of the INSPIRA ART500 device recently approved by the U.S. Patent office?
How many claims of the innovation were found to be novel?
What is the purpose of the VORTX™ system?
How does the INSPIRA ART500 device empower breathing in awake patients?
Who is the CEO of Inspira Technologies?
